Clinical trial
A Study of Everolimus in Combination With Imatinib in Metastatic Melanoma
NCT00402662 · Yale University, Other · Terminated
Key facts
| NCT number | NCT00402662 |
|---|---|
| Title | A Study of Everolimus in Combination With Imatinib in Metastatic Melanoma |
| Official title | A Phase II Study of Everolimus in Combination With Imatinib in Metastatic Melanoma |
| Lead sponsor | Yale University, Other |
| Collaborators | Novartis Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Metastatic Melanoma |
| Intervention type | Drug |
| Interventions | everolimus, Imatinib |
| Enrollment | 3 |
| Start date | Feb 1, 2006 |
| Primary completion | Jun 1, 2006 |
| Completion | Jun 1, 2006 |
| First posted | Nov 22, 2006 |
| Last update posted | Dec 18, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: